Written question asked by Neil Duncan-Jordan (Labour) on Tuesday, 3 February 2026, in the House of Commons. It was due for an answer on Monday, 9 February 2026 (named day). It was answered by Zubir Ahmed (Labour) on Monday, 9 February 2026 on behalf of the Department of Health and Social Care.
Leukaemia: Babies
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of medication available on the NHS to treat Acute Myeloid Leukaemia in babies.
- Answer
-
Acute myeloid leukaemia is rare in babies, as there are approximately 10 cases in England each year. Standard upfront chemotherapy is available but options for patients who do not respond to standard chemotherapy or relapse are limited. NHS England encourages clinicians to submit proposals to expand the range of clinical commissioning policies, helping to ensure that patients are able to access the latest, evidence-based treatments and care.
The Department continues to work with NHS England, the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence to support the development of new treatments for rare paediatric cancers.
Secondary information
- Type
- Written question
- Reference
- 110686
- Session
- 2024-26
- Subjects
- Babies Drugs NHS Leukaemia
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-02-09 11:14:01 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/110686
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/110686
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/110686